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Objectives: To control the emerging threat of antimicrobial resistance, international policy appeals for appropri-
ate monitoring of antimicrobial usage (AMU) at supranational, species and farm level. The aim of this study was
to quantify AMU in broilers at farm and flock level in nine European countries.
Methods: Antimicrobial treatment data of one flock and purchased antimicrobials over one year were collected
at 181 European broiler farms. Afterwards AMU was quantified using treatment incidence (TI) per 100 days
based on Defined Daily Dose (DDDvet), Defined Course Dose (DCDvet) or Used Daily Dose (UDDvet) values. Total
AMU at flock level was obtained by summing the TIDDDvet of all treatments in the sampled flock (TIDDDvetFl*).
Results: The median TIDDDvetFl* was 9.0 (95% CI 5.5–10.8), meaning that broilers were treated with antimicro-
bials during 9% of their rearing period. TIDDDvetFl* varied considerably within and between countries. However, in
every country at least one untreated flock was present. Average TIDDDvetFl* at country level ranged from 3.3 to
36.7. Polymyxins, extended-spectrum aminopenicillins and fluoroquinolones were the most used antimicrobials,
accounting for 26%, 26% and 18% of total AMU, respectively. Twenty-six percent of the farms started a treat-
ment on day 1 of production, and 49% of overall AMU was administered within the first week.
Conclusions: Results show that rearing broilers without AMU is feasible. However, a huge variation in AMU in
terms of amount, moment of administration and antimicrobial classes was observed. This shows that there is
still ground to be covered when it comes to AMU on broiler farms.
Introduction
Antimicrobials have shaped modern medicine. Major surgeries
have become routine procedures thanks to the prophylactic use of
antimicrobials. However, due to the exposure of bacteria to antimi-
crobials, many intrinsically susceptible bacteria have acquired anti-
microbial resistance (AMR) mechanisms, which result in a selective
advantage when the bacteria are exposed to antibiotics. This led
to the recognition by the WHO of AMR as one of the major threats
to public and animal health.1
The strongest driver for the selection of AMR is antimicrobial
usage (AMU), both in human and veterinary medicine.2–4 Broiler
production is likely to be responsible for a large share of animal-
related AMU. It is not only the second biggest European meat-
producing industry, but also a very intensive animal production
system.5 Antimicrobials used at flock level are administered via
drinking water, which is the only feasible administration route.
However, this type of mass medication leads to frequent exposure
to antimicrobials of large numbers of animals and often results in
improper dosing of the administered antimicrobials.6,7
Phasing out antimicrobial growth promotors in 1999, and the
complete ban in 2006, were the first important measures towards
constraining AMU in animals in Europe.8 Following these regula-
tions, several studies observed an increase in therapeutic AMU.9–11
In 2005, the WHO published the first list of critically important anti-
microbials (CIAs), updated to the fifth revision in 2017, with the
aim of reducing the use of CIAs in food animal production.12–14 In
2009, the European Surveillance of Veterinary Antimicrobial
Consumption (ESVAC) was founded, which succeeded in the
harmonized collection of European antimicrobial sales data. The
results have repeatedly demonstrated huge differences between
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countries in the amounts of antimicrobials sold.15 However, be-
cause data are not collected by species, differences in dosage can-
not be accounted for, nor does the used indicator allow monitoring
of AMU at farm or flock level. Moreover, the indicator’s denomin-
ator includes all biomass produced per country, which is highly
influenced by the composition of the national animal population.
Therefore, reports on AMU based on sales figures by country re-
main a crude measurement with necessary approximations,16
and conclusions on usage profiles based upon the ESVAC data are
debatable.17 Avoiding approximations is only possible when col-
lecting the actual use of antimicrobials at the farm itself.18
However, multi-country studies collecting AMU data in broilers at
farm level are laborious and time-consuming and to our know-
ledge inexistent.
To optimize the control of AMU in Europe, appropriate and
detailed supranational monitoring of antimicrobials administered
at animal species and farm level is required.2,18,19 Therefore, the
aim of this study was to quantify AMU in broilers at farm and flock
level in nine European countries in a standardized manner to gain
better insights into AMU in broilers. All data was collected within
the EU-FP7 ‘Ecology from Farm to Fork Of microbial drug
Resistance and Transmission’ (EFFORT) project, which investigates
the epidemiology and ecology of AMR in food-producing animals,
the environment and humans to quantify AMR exposure pathways
for humans.
Materials and methods
Study sample and data collection
In a cross-sectional survey, AMU data was collected at 20 farms (21 in
country A) in each of the nine participating countries: Belgium, Bulgaria,
Denmark, France, Germany, Italy, Poland, Spain and the Netherlands. The
selection of farms in each country was based on inclusion criteria to obtain
a group of farms that were comparable between and within countries. All
farms were conventional and had all-in all-out production with a maximum
slaughter age of 50 days. No slow-growing breeds or stocking density lower
than 10 birds/m2 were allowed. In each country, farms were selected based
on these criteria in an agreement with local farming organizations, and par-
tially also based on convenience (e.g. distances to farms); regional stratifi-
cation was used whenever possible. As a result, the 20 farms cannot be
considered representative for broiler production in a country. Countries
were anonymized (letters A to I). A detailed description can be found in
Appendix A (Appendices available as Supplementary data at JAC Online).20
Participating farms were visited between May 2014 and June 2016.
A questionnaire was completed in collaboration with the farmers to provide
information on farm technical and AMU data. A strict questionnaire proto-
col in combination with training for the researchers was used to minimize
interview bias (Appendix B). Information was listed for each antimicrobial
treatment given to the sampled flock. These data are referred to as the
treatment data (shown with a superscripted single asterisk). Furthermore,
data on purchased antimicrobials during the year preceding the visit was
collected. When available information did not cover a whole year, data
were extrapolated. These data are referred to as the purchase data (shown
with a superscripted double asterisk).
AMU quantification
AMU was quantified in a standardized manner using treatment incidence
(TI) as described by Persoons et al.7 The numerator (Table 1) equals the
total amount of active substance (AS) administered (treatment data) or
purchased (purchase data). In the denominator, three different parameters
can be used, resulting in three different formulas (Table 1): Defined Daily
Dose (DDDvet), Defined Course Dose (DCDvet) or Used Daily Dose (UDDvet).
Hereby, TI is expressed as the number of DDDvet or UDDvet administered
per 100 animal-days at risk or the number of days per 100 animal-days
that the flock is receiving a dose of antimicrobials, reflecting the percentage
of time that a broiler is treated with antimicrobials in its life. When using
DCDvet, TIDCDvet expresses the number of treatment courses per
100 animal-days. When using UDDvet, the formula to calculate TIUDDvet
can be simplified (Table 1), as UDDvet, which expresses the administered
dose of AS per day per kg of broiler, appears both in the numerator and in
the denominator of the formula.
DDDvet and DCDvet reflect the assumed average dose of a drug for its
main indication per day per kg of broiler and per treatment course per kg of
broiler, respectively. For antimicrobials registered for broilers, most of these
values have been defined by ESVAC.21 Whenever combination products
were not on the ESVAC list and the dose of one or both ASs were substan-
tially different from the single AS products, DDDvet and DCDvet values were
obtained from the summary of product characteristics (SPC). In all other
cases of combination products, the assigned DDDvet/DCDvet values were
the same as for the single AS antimicrobials.21
When using antimicrobial treatment data, ‘kg of animal at risk’ was cal-
culated by multiplying ‘standard weight’ and ‘number of animals at the
start of the sampled flock’. For purchase data, ‘kg of animal at risk’ was
determined by multiplying ‘standard weight’ and ‘number of animals deliv-
ered to slaughter yearly’. ‘Standard weight’ was set to be 1 kg in accordance
with the ESVAC guidelines.22 For both treatment and purchase data, ‘num-
ber of days at risk’ for each country was set to be equal to the average dur-
ation of the rearing period within that country (Table S1).
The different types of TI were calculated based on the treatment data
(TIDDDvet*, TIDCDvet*, and TIUDDvet*) and a second time based on the purchase
data (TIDDDvet**, TIDCDvet**). For the treatment data, UDD was sometimes
expressed per ‘kg of feed’ or ‘litre of water’ instead of per ‘kg of animal’.
Therefore, assumptions were made concerning standard daily feed and water
intake for a bird of 1 kg, which were set at 120 g and 210 mL, respectively.
TIDDDvet, TIDCDvet, and TIUDDvet were calculated at flock level by adding up the
TIs of all treatments, resulting in TIDDDvetFl*, TIDCDvetFl* and TIUDDvetFl* respect-
ively. TIDDDvet and TIDCDvet were also calculated at farm level by adding up the
TIs of all the purchased products, resulting in TIDDDvetFa** and TIDCDvetFa**.
Data processing
Data were entered into EpiData version 3.1 software (EpiData Association,
Denmark) by the researchers who visited the farms. Data quality checks
were performed using ActivePerl 5.24.1 (ActiveState Software Inc.) and SAS
9.4 (SAS Institute Inc., Cary, NC, USA). Subsequently, SAS was used for data-
base management. Finally, 10% of all questionnaires were entered twice
and compared in SAS to check for data entry quality. All inconsistencies
were corrected and datasets from countries with a high percentage of
inconsistencies (.5%) were thoroughly re-evaluated by the respective insti-
tutes. Next, data required for AMU quantification were imported into
Microsoft Excel and a second, more in-depth, quality control was performed
prior to the AMU quantification.
Statistical analysis
Descriptive statistics were calculated in ExcelV
R
2016. Since TIs at country
level deviated considerably from normality, even after log10 transform-
ation, minimum, median and maximum results are reported. Median val-
ues are reported with 95% CI based on the adjusted bootstrap percentile
method with 1000 replicates.23 To compare different systems of data col-
lection and quantification, results of all TIs were compared with
Spearman’s rank correlation tests in R version 3.4.0 software (https://cran.r-
project.org). Only for the indicators based on purchase data, results from
country I were not included, as the sampled period only covered one
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month, making extrapolation to a period of 1 year unreliable. Seventy per-
cent of the remaining farms reported data that covered at least 9 months.
Results
AMU at flock level
Based on the treatment data, the median TIDDDvetFl* over all flocks
was 9.0, with a large variation, ranging from 0 to 174.5. This vari-
ation was observed within each group of flocks in each country,
with both untreated and treated flocks in every country. In total,
230 treatments, which were all group treatments, were registered
over 114 flocks, meaning that 67 flocks (37%) did not receive anti-
microbials. Countries C, F and I had a higher percentage of untreat-
ed flocks, with 85%, 75% and 85%, respectively, compared with
only 5% in countries D and G. Nonetheless, the highest TIDDDvetFl*
in country C (46.3) was almost equal to the one from country H
(46.1), although there were four times more untreated flocks in
country C (n"17). The variation in AMU between flocks within the
same country and between flocks of different countries is pre-
sented in Figure 1 and Table 2.
When comparing different indicators, results correlate only
moderately when comparing estimates based on purchase data
with estimates based on treatment data of one rearing period,
with a correlation coefficient of 0.54 for TIDDDvetFl* and TIDDDvetFa*.
However, they correlate strongly when comparing different quan-
tification methods within the same dataset, ranging from 0.91 to
0.99 (Table 3). Further description of the results is based on the
treatment data, as this allows for a more detailed description, and
will solely be based on TIDDDvetFl* because of the high correlations
within the treatment dataset.
AMU divided over the different antimicrobial classes
Polymyxins, which were represented only by colistin (28 treat-
ments), and extended-spectrum penicillins (ES penicillins), which
were represented by amoxicillin (60 treatments) and ampicillin
(4 treatments), were the most frequently used antimicrobial
classes. Each class represented 26% of total AMU. Polymyxins was
the most administered antimicrobial class in country H (43%) and
country D (50%) and was used in five out of nine countries. ES peni-
cillins and fluoroquinolones (17% of total AMU) were used in all
countries, except in country C, where 72% of total AMU consisted
of tetracyclines. In countries A, D and I, ES penicillins was the most
commonly used class of antimicrobials, representing 31%, 30%
and 45% of the each country’s total AMU, respectively. In country
G, fluoroquinolones was the most frequently used antimicrobial
class, representing 31% of total usage within that country. Table 4
shows an overview, including ATCvet codes.24
Indication for treatment
Intestinal disorders were the most common indication for treat-
ment (45%), followed by colibacillosis (16%) and omphalitis (12%)
(Table 5). Other indications only represented incidental treat-
ments. Variation between countries was rather limited, except for
a few outliers within certain indications such as reported respira-
tory disorders in country A (n"9) and country G (n"10).
AMU usage over the period of one production cycle
In 26% of the flocks, antimicrobial treatments were initiated on
the first day of production, followed by 9% and 5% on days 2 and
3, respectively (Figure 2). As a result, 38% of the flocks were being
treated with antimicrobials on day 3. Subsequently, the percent-
age of farms where antimicrobials were being administered grad-
ually declined to 2% on day 13, followed by a slight increase
resulting in a fluctuation around 10% during the third and fourth
week. No new treatments were initiated from day 37 onwards, ex-
cept for one on day 38 and one on day 42. The early AMU peak was
present in all countries, ranging from 10% of the flocks being
treated in country C to 65% in country E (Table S2). In the treated
flocks from country C (n"3), all treatments were administered
within the first three days of production.
Indication for treatment also varied depending on the age of
the broilers. On day 1 the ‘non-specific’ indication was the most
frequently used reason to start treatment, accounting for 23% of
treatments started on day 1. Over the whole first week, omphalitis
was the most frequently reported indication for treatment (27%).
Intestinal disorders were most frequently reported between the
third and fifth weeks (67%) (Table S3). Furthermore, the type of
antimicrobial used varied widely throughout the rearing period.
While lincomycin/spectinomycin was only used in treatments initi-
ated on day 1 (n"16) and day 2 (n"3), ES penicillin treatments
(n"64) were registered on 29 different days during the six weeks
of production. Fluoroquinolones (n"50) were mainly used at the
Table 1. Formulas to quantify AMU using TI
Variable Formula Result
Numerator*
UDDvet mg=kg=dayð Þ  treatment duration daysð Þ  no:
of animals treated  standard weight per animal ðkgÞ total amount of AS administered
Numerator** package size  no: of packages purchased  concentration of AS in the product total amount of AS purchased
TIDDDvet
total amount of AS administered or purchased ðmgÞ
DDDvet mg=kg=dayð Þno: of days at riskkg of AAR  100 AAR no. of DDDvet/100 broilers at risk/day
TIDCDvet
total amount of AS administered or purchased ðmgÞ
DCDvet mg=kg=courseð Þno: of days at riskkg of AAR  100 AAR no. of DCDvet/100 broilers at risk
TIUDDvet treatment durationno: of animals treatedno: of days at riskno: of AAR  100 AAR no. of UDDvet/100 broilers at risk/day
TIDDDvet/DCDvet/UDDvet, TI calculated with DDDvet/DCDvet/UDDvet as a parameter to take dosage into account; AAR, animals at risk.
*Numerator is based on the treatment data.
**Numerator is based on the purchased data.
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beginning of production (n"30). A similar pattern was seen for
the aminoglycosides, with seven out of the nine treatments being
applied on day 1 (Table S4).
Discussion
Previous studies have described AMU in multiple species;9,11,25
others only studied one species.7,26–28 In most cases they only
covered one country or did not use the same methodology
across countries.17 When multi-country studies on AMU imple-
mented the same methodology, results were mainly based on
sales data, prohibiting detailed description of AMU at farm or
flock level or direct species comparison.8,11,15 To our knowledge
this is the first multi-country study that reports on AMU in
broilers in such detail, using standardized sampling and AMU
quantification protocols.
There is no consensus on which indicator provides the most
valuable information when quantifying AMU, as characteristics
such as resolution, ability to assess exposure and comparability dif-
fer between indicators.16 To describe and compare AMU for broilers
at flock level, it is required to use an indicator with a high spatial
resolution (on-farm registration) and high comparability between
flocks. TIDDDvet fulfils almost all requirements described by
Collineau et al.,16 as quantification is based on treatments
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Figure 1. Comparison of antimicrobial TI at flock level (TIFl) across nine European countries (A–I). TI is shown as the number of DDDvet (TIDDDvet, top
left corner), DCDvet (TIDCDvet, top right corner) and UDDvet (TIUDDvet, bottom centre) per 100 broiler-days at risk. TI represents the percentage of time
that a broiler was treated with antimicrobials in its life. Antimicrobial treatment data were obtained from 181 broiler farms with 20 farms in each
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sents the median. The black cross within each box plot represents the average. The whiskers extend to the most extreme data point within the range
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registered at flock level and takes into account a standardized
daily dose (DDDvet) and treatment length. Because of the need to
work with a standardized feed and water intake, a standardized
animal weight was used instead of the actual animal weight at
treatment. Comparability between flocks was achieved by setting
up inclusion criteria (Appendix A), resulting in data from compar-
able broiler production systems across Europe.
The correlation of 0.54 between indicators from different data-
sets (treatment versus purchase data) is inherent to the type of
data collected and can be explained by the different time frames
that are covered by the datasets. Hence, an untreated flock does
not equal a non-using farm, as other flocks at that farm might be
faced with a disease outbreak, possibly leading to higher AMU.
DDDvet values were determined by ESVAC based on the recom-
mended dosage found in the SPC of the drugs in nine European
countries.29 However, ESVAC reports these values as technical units
of measurement that should not be considered to reflect the actual
daily dose in all circumstances, as they are often a compromise be-
tween different approved doses for the same AS in different coun-
tries or different commercialized products in the same country.21,30
In contrast, the UDD can differ between and within farms, as it rep-
resents the truly administered dose of a drug on the farm itself. The
flexibility of UDD makes the indicator robust to deviation from the
SPC and is therefore a better reflection of the true exposure at flock
level.28,31,32 Yet, the limitation of the UDD is the requirement for
very detailed herd-level data collection. Nonetheless, from the
Table 4. Proportion (%) by antimicrobial class of the amount of antimicrobials used on 181 participating broiler flocks in nine European countries (20
flocks/country, 21 flocks in country A)
Antimicrobial classa ATCvet code
Country
A (%) B (%) C (%) D (%) E (%) F (%) G (%) H (%) I (%) total (%)
Aminoglycosides QJ01GB — — — — — — 5 6 — 2
ES penicillins QJ01CA 31 23 — 30 24 21 27 18 45 26
Amphenicols QJ01BA — — — — — — 2 — — ,1
Fluoroquinolones QJ01MA 15 7 — 6 36 12 31 19 31 18
Linco/spec QJ01FF52 14 28 28 — — — 1 — — 5
Lincosamides QJ01FF — — — — — — — — 23 1
Macrolides QJ01FA ,1 — — 6 — — 1 7 — 3
Other quinolones QJ01MB 3 — — — — — — — — ,1
b-lact-sens penicillins QJ01CE — — — — — — 3 — — 1
Polymyxins QJ01XB — 20 — 50 30 — 14 43 — 26
Tetracyclines QJ01AA 16 21 72 — — 19 15 7 — 11
Trim/sulfa QJ01EW 21 — — 9 10 48 2 — — 8
Proportions are shown at country level (columns A to I) and in total (total column). All 230 antimicrobial treatments from day 1 to slaughter on the
181 flocks were quantified using TI based on DDD (DDDvet, TIDDDvet*). Linco/spec, lincosamides/spectinomycin; Trim/sulfa, trimethoprim/sulphona-
mides; b-lact-sens penicillins, b-lactamase-sensitive penicillins.
aAntimicrobial classes that are not in this table were not used.
Table 5. Distribution (%) by indication for treatment of the total number of treatments within a country (columns A to I) and in total
Indication for treatment
Country
A
(%, n"37)
B
(%, n"15)
C
(%, n"3)
D (%,
n"48)
E
(%, n"29)
F
(%, n"7)
G
(%, n"58)
H
(%, n"28)
I
(%, n"4)
total
(%, n"229)
Intestinal disorder 35 13 67 90 38 29 36 29 50 45
Colibacillosis 3 27 — 4 31 43 14 36 — 16
Omphalitis 22 33 — — 10 — 19 — — 12
Respiratory disorder 24 7 — 2 — — 17 4 — 10
Locomotor disorder 8 20 33 — 3 29 7 — — 6
General disorder 3 — — 4 10 — 2 — 50 4
Mortality 3 — — — 7 — 2 — — 2
Non-specific 3 — — — — — 3 32 — 5
Data shown are based on 229 antimicrobial treatments out of 230 treatments that were registered during the rearing period from day 1 to slaughter
of 181 broiler flocks in nine European countries (20 flocks/country, 21 flocks in country A). Indication for treatment was missing for one treatment
and is therefore not shown in the table.
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obtained results it appears that TIDDDvetFl* and TIUDDvetFl* seem to
correlate strongly (0.93). This does not mean that at flock level the
parameters are comparable in all circumstances as the biggest
range for these parameters is represented by a flock where
TIDDDvetFl* equalled 121.0, compared with 12.2 for TIUDDvetFl*.
However, on a meta level, the results did correlate quite well. This is
important since DDDvet is more convenient to report in a harmon-
ized manner compared with the detailed actual exposure as meas-
ured by means of the UDDvet. The TI was also calculated using
DCDvet to describe the number of courses rather than the number
of treatment days. Again, results for both TIDDDvet and TIDCDvet
appeared to be very strongly correlated (0.99) and provided com-
parable information. The only difference was the scale, which is on
average four and a half times smaller in TIDCDvet, reflecting the truly
observed average treatment duration of 3.5 days. The methodology
used to determine DCDvet values29 and outliers regarding treat-
ment duration may explain the small difference between the aver-
age treatment duration (3.5 days) and the average ratio between
TIDDDvet and TIDCDvet (4.5 days).
This study has clearly demonstrated that AMU differs consider-
ably between flocks, both within and between countries. The same
finding was previously reported in a study on AMU in pigs in four
European countries.27 In addition, other studies conducted at flock
or farm level also reported a large variation.7,9,26,28 In each country
there were farms that succeeded in rearing the sampled flock with-
out antimicrobial treatments and flocks that stood out by higher
usage. This shows that there is substantial room for improvement
towards more responsible AMU in the majority of the farms.
Three AMU classes represented 70% of all the antimicrobials
administered in this study. However, each country had a different
distribution of antimicrobial classes used. This variation between
countries was also observed for pigs27 and for AMU in veterinary
medicine in general, as reported in ESVAC reports.33 These varia-
tions may be the result of differences in availability of registered
antimicrobial products, presence or absence of specific legislation
to reduce the use of especially Highest Priority CIAs (HPCIAs), or
different levels of clinical resistance.4,18,27,34 Moreover, other
explanations such as economic incentives and experience of the
veterinarian have been suggested.35 By publishing a list of CIAs,
the WHO has provided a reference that can be used in risk man-
agement by different stakeholders, with the aim to reduce the vet-
erinary use of those antimicrobials pivotal for human healthcare.
Nevertheless, fluoroquinolones and polymyxins belonged to the
most commonly used classes in this study, despite being on the
HPCIA list.13 However, polymyxins were only added to the list in
2016 while, for the current study, data collection was conducted
between 2014 and 2016.
AMU peaked during two moments of the rearing period. The
first and highest peak was detected in the first two days of pro-
duction and represented 27.8% of the total AMU. This peak is likely
linked to routinely prophylactic/metaphylactic AMU to prevent
diseases such as omphalitis and colibacillosis. This type of mass
medication is considered as a cheap and easy solution for disease
prevention. Recently, the European Commission published a re-
port with guidelines for prudent use of antimicrobials in veterinary
medicine where they call for action regarding the prophylactic
and recurrent group medication of poultry, which is often admin-
istered before or after transport of day-old chicks to prevent losses
in productivity.36
During the first peak, omphalitis was the most commonly
reported indication, which is probably related to faecal contamin-
ation of eggs. This can lead to Escherichia coli infections at the mo-
ment of hatching, resulting in death or yolk sac infections.37 The
‘non-specific’ indication represented 23% of the treatments on the
first day of production. Non-specific treatments are problematic as
this is in contravention of guidelines on responsible AMU, which in-
dicate the requirement of a proper diagnosis before treatment. A
solution to avoid inappropriate AMU in day-old chicks can be found
in good management on arrival at the farm.36 However, within the
pyramidal structure of the broiler industry, many factors influence
day-old chick quality,38,39 which emphasizes the importance of
good management throughout the entire production chain.
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Figure 2. The histogram shows the proportion (%) of the broiler flocks (on the y-axis) where treatment with antimicrobials was initiated on a certain
day of production (on the x-axis). The graph shows the proportion (in percentage) of the 181 broiler flocks (on the y-axis) that were being treated
with antimicrobials on a certain day of production (on the x-axis). The x-axis represents the age of the broilers in days as it covers one rearing period
from day 1 until day 43. Data shown are based on all 230 antimicrobial treatments that were registered during the rearing period from day 1 to
slaughter of 181 broiler flocks in nine European countries.
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The second treatment peak stretches out over a larger time
frame, starting at the beginning of week 3 and slowly disappearing
after week 4. In broilers, gastrointestinal problems typically occur
during this production period.40 In the field, these intestinal prob-
lems are often referred to as dysbacteriosis. The aetiology of this
disorder is not yet fully understood but is most certainly multi-
factorial,41 which might explain the high usage of ES penicillins,
such as amoxicillin.
In this study we quantified AMU in broiler farms of nine
European countries, comparing TIDDDvet, TIDCDvet and TIUDDvet.
These different indicators did not show large differences in results
when quantification was performed within the same dataset. The
type of dataset used (treatment versus purchase), on the other
hand, showed substantial differences. When focusing on the treat-
ment data, a huge variation in AMU, in terms of amount adminis-
tered, moment of treatment and antimicrobial classes, was
observed both within and between countries. This calls for further
research to determine the drivers causing this variation, so correct
actions towards more responsible AMU can be taken.
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